G. Kloppel; E. Solcia; D.S. Longnecker; C. Capella; Leslie H. Sobin Springer-Verlag Berlin and Heidelberg GmbH & Co. KG (1996) Pehmeäkantinen kirja 49,60 € |
|
Histological Typing of Tumours of the Exocrine Pancreas This is a histological classification of tumours and tumour-like lesions of the exocrine pancreas which also includes those tu- mours showing a mixture of exocrine and endocrine elements. The classification is based principally on standard microscopic observations, but whenever indicated it incorporates diagnosti- cally valuable immunohistological findings. In addition, the most important immunohistological findings which are helpful in cat- egorizing pancreatic tumours are summarised in Table 1. The major guideline of this classification scheme is the group- ing of the pancreatic exocrine tumours according to their biologi- cal behaviour. Thus, the neoplasms are broadly divided into benign (adenoma) and malignant tumours (carcinoma). How- ever, in recent years we have learned that this division is not a sharp but rather a gradual transition. We therefore added a third group which we call "tumours of uncertain malignant potential" representing a borderline category analogous to that recognized for some ovarian tumours. This group includes mucinous cystic tumour, intraductal papillary-mucinous tumour and solid- pseudopapillary tumour. These neoplasms are defined by the grade of dysplasia and/or potential to become malignant. Mucinous cystic tumours of uncertain malignant potential, for instance, exhibit moderate epithelial dysplasia, but do not show severe dysplasia/carcinoma in situ changes, nor carcinomatous invasion of the cyst wall or the adjacent pancreatic tissue. Solid- pseudopapillary tumour has a benign looking histological ap- pearance, but metastases may occur. Biologically, all these neoplasms are primarily slow-growing lesions and have an excel- lent prognosis when adequately treated by complete resection.
Tilaustuote | Arvioimme, että tuote lähetetään meiltä noin 4-5 viikossa | Tilaa jouluksi viimeistään 27.11.2024
|